By | 03 Aug 2022 at 7:00 PM

Novavax Inc: * EMA – PRAC HAS CONCLUDED THAT MYOCARDITIS AND PERICARDITIS CAN OCCUR FOLLOWING VACCINATION WITH NUVAXOVID

* EMA SAYS PRAC RECOMMENDING LISTING MYOCARDITIS AND PERICARDITIS AS NEW SIDE EFFECTS IN PRODUCT INFORMATION FOR NUVAXOVID * EMA: PRAC HAS ALSO REQUESTED THAT MARKETING AUTHORISATION HOLDER OF NUVAXOVID PROVIDES ADDITIONAL DATA ON RISK OF SIDE EFFECTS OCCURRING Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)